Drug Trial Radar · NCT05881837
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
249
Actual
Start
Jun 13, 2023
Primary completion
Oct 13, 2024
Study completion Oct 13, 2024
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.
Conditions
- Overweight or Obesity
Interventions
HRS9531 injectionDrug
HRS9531 injection: dose level 1 for 32 weeks; level 2 for 20 weeks
HRS9531 injectionDrug
HRS9531 injection: dose level 2
HRS9531 injectionDrug
HRS9531 injection: dose level 3
HRS9531 injectionDrug
HRS9531 injection: dose level 4
HRS9531 injection PlaceboDrug
Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks; HRS9531 injection level 2 for 20 weeks
HRS9531 injection PlaceboDrug
Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks; HRS9531 injection level 2 for 20 weeks
HRS9531 injection PlaceboDrug
Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks; HRS9531 injection level 2 for 20 weeks
HRS9531 injection PlaceboDrug
Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks; HRS9531 injection level 2 for 20 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weightTime frame: Week 0, Week 24
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Huadu District People's Hospital of Guangzhou
Guangzhou, Guangdong, China
The People's Hospital of Longhua. Shenzhen
Shenzhen, Guangdong, China
Sencond Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The First Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The Central Hospital Of Huangshi
Huangshi, Hubei, China
The Third People's Hospital of Hubei Province
Wuhan, Hubei, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Lianyungang Hospital of TCM
Lianyungang, Jiangsu, China
The First People's Hospital Of Lianyungang
Lianyungang, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
North Jiangsu People's Hospital
Yangzhou, Jiangsu, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Shengjing Hospital Of China Medical University
Shenyang, Liaoning, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Second Hospttoal of Shanxi Medical University
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'an Medical College
Xian, Shanxi, China
Chengdu Second People's Hospital
Chengdu, Sichuan, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
The First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.